tbuckley/cabot-search huggingface dataset:
Oncologist and primary care physician attitudes and practices toward cancer survivor follow-up care in an integrated health system.
Authors: Bijal A. Balasubramanian, Katelyn K Jetelina, Simon Craddock Lee
Journal: Journal of Clinical Oncology (2016)

105 Background: Previous research using nationally representative data showed significant differences between primary care physician (PCP) and oncologists’ attitudes and practices with respect to care of cancer survivors and called for more effective communication and coordination to improve care. This study compared PCP and oncologists’ attitudes and practices for follow-up cancer care within an integrated health system sharing a common electronic health record and clinical infrastructure to examine whether the integrated setting facilitated communication and coordination between PCPs and oncologists. Methods: 41 PCPs and 24 oncologists (response rate = 52%) affiliated with an integrated safety-net health system completed a validated survey. The survey assessed PCP and oncologists’ preferred models for delivering care, attitudes towards follow-up care, and cancer surveillance practices in this setting. Results: 41% of PCPs preferred an oncologist-led care delivery model as compared to 21% of oncologists. More PCPs than oncologists (73% vs 58%) agreed that PCPs have the skills necessary to initiate cancer surveillance. Yet, PCPs more often disagreed (56% vs 42% of oncologists) that they should have primary responsibility for providing cancer follow-up care. PCPs and oncologists differed significantly over cancer surveillance practices. Oncologists more consistently reported that PCPs ordered tests for cancer surveillance, evaluated patients for cancer recurrence and for adverse physical and psychological effects of cancer or its treatment, as well as managed pain and adverse outcomes of cancer treatment. PCPs, however, did not report equivalent ordering for these services. Conclusions: Even within an integrated health system, we found significant uncertainty as to who is responsible for care of cancer survivors. Oncologists more commonly assigned responsibility for cancer survivorship care to PCPs than PCPs recognized. This imbalance indicates many cancer survivors may not be receiving recommended care. Consensus guidelines are needed to delineate shared responsibilities for cancer survivors between primary care and oncology specialty care physicians.
P20.01 MEVITEM: A European, randomized, open-label Phase I/II study of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent or refractory medulloblastoma presenting an activation of the Sonic Hedgehog pathway
Authors: D. Frappaz, D. Meyronnet, G. Garin, F. Laigle-Donadey, E. Le Rhun, A. Bonneville-Levard, J. Frenel, A. Idbaih, C. Gourmelon, O. Chinot
Journal: Neuro-Oncology (2016)

Therapeutic options are limited for refractory/relapsed adult medulloblastoma with activation of sonic hedgehog pathway (SHH-MB). Inhibition of this pathway may offer an attractive therapy. Vismodegib suppresses SHH signaling by binding to and interfering with the SMO transmembrane receptor. We postulate that vismodegib together with chemotherapy may kill more tumor cells than chemotherapy alone by blocking cell proliferation at different molecular levels (“vertical association strategy”). MEVITEM is a multicenter, randomized (2:1 ratio), open-label, Phase I/II aiming to evaluate the safety and clinical activity of the association vismodegib (V: daily 150mg/d, po) + temozolomide (T: D-5: 150 mg/m2 for Cycle 1 and 200 mg/m2for subsequent cycles) versus T alone in adult patients with recurrent or refractory SHH-MB. Main eligibility criteria are: histologically confirmed recurrent or refractory SHH-MB for which no known curative therapy exists, not previously treated with T, with evidence of measurable disease and documented activation of SHH pathway. Pathological review and analysis of SHH pathway are performed centrally by IHC. This Phase I/II includes i) a safety Run aiming to evaluate the safety of V+T and ii) a Phase II part aiming to evaluate the clinical activity of V+T measured by the 6-month non-progression rate. Patients enrolled in the safety Run are included in the evaluation of the Phase II part. Considering that V+T would be uninteresting if 6-month non-progression rate ≤ 30% and promising if ≥ 55% and using Simon’s optimal two-stage design (type I error rate of 5%, power of 80%), a sample size of 25 evaluable patients is required for Arm V+T (including 9 in stage I). The sample size in Arm T alone is 13 patients. Considering the rarity of the disease, the few therapeutic options and the promising results reported with V in adult SHH-MB: the Sponsor considered the enrolment of patients previously treated by T in a 3rdindependent and parallel arm with V as single agent (Arm C). To date, 18 patients were enrolled (Arm V+T: 7, Arm T: 4, Arm C: 7), the Phase II part is ongoing.
CA-125 as a Marker for the Early Diagnosis of Hepatic Veno-Occlusive Disease Following Hematopoietic Stem Cell Transplantation.
Authors: Tsila Zuckerman, Shani Ben Harush, Irit Avivi, Israel Gavish, Nuhad Haddad, Riva Fineman, Eldad Dann, Ron Hoffman, Benjamin Brenner, Jacob M. Rowe, Eli Zuckerman
Journal: Blood (2004)
The incidence and the mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma.
Authors: N. Shinohara, M. Takahashi, T. Kamishima, H. Ikushima, N. Otsuka, A. Ishizu, A. Sazawa, H. Kanayama, K. Nonomura
Journal: Journal of Clinical Oncology (2010)

e15097 Background: Hypothyroidism is one of the commonly observed adverse events of sunitinib in patients (pts) with metastatic renal cell carcinoma (MRCC). In order to elucidate the underlying mechanisms, we investigated the temporal volumetric and functional changes and histological changes of thyroid gland in MRCC pts who received sunitinib. Methods: Inthe present retrospective study with 17 MRCC pts (7 females and 10 males, age range 23-78 yr), the volume of thyroid gland and thyroid function were measured at baseline and during the treatment. With regard to the thyroid function at baseline, there were 1 unknown, 4 subclinical hypothyroidism and 12 euthyroid pts. The volume of thyroid gland by CT volumetry was measured utilizing the CT data obtained for tumor assessment. The median duration of treatment with sunitinib was 6 cycles (range, 1-23 cycles). Histological evaluation of thyroid gland was performed in the patients who underwent the autopsy. Results: Median reduction in volume of thyroid gland compared to that at baseline was 30% (0-25% 8 pts, 25-50% 1 pt, 50-75% 4 pts, 75-95% 4 pts). The median treatment cycle of sunitinib in 8 patients with more than 50% reduction in volume [thyroid atrophy (TA) group] was 13.5 (range, 6-23), which was considerably longer than that in the remaining 9 patients [non-TA group] (median 2 cycles; range, 1-6). The tumor response by the RECIST criteria was 88% (7/8 pts) in the TA group and 22% (2/9 pts) in the non-TA group. While 7 of 8 patients in the TA group experienced hypothyroidism, only 1 of 9 patients in the non-TA group experienced hypothyroidism. The increase in volume of thyroid gland was not observed in 3 patients of the TA group who discontinued sunitinib treatment. Histological evaluation of thyroid gland in 4 autopsied patients demonstrated the atrophy of thyroid follicle and the degeneration of follicular epithelial cells without significant changes in vascular distribution of thyroid gland. Conclusions: In addition to hypothyroidism, thyroid atrophy is also observed following suintinb treatment in MRCC pts. Thyroid atrophy as well as dysfunction may be brought about from the direct effects of sunitinib on follicular epithelial cells of thyroid gland. No significant financial relationships to disclose.
Foxp3+ CD62L+ Tregs induced by EPIT have the potency to suppress effector T cells proliferation in specific and bystander conditions
Authors: Benjamin Pelletier, Lucie Mondoulet, Melanie Ligouis, Veronique Dhelft, Camille Plaquet, Christophe M. Dupont, Pierre-Henri Benhamou, Hugh A. Sampson
Journal: Journal of Allergy and Clinical Immunology (2017)
Treatment (trmt) outcome in lung transplant (LTx) recipients who develop lung cancer (LC): A Cleveland Clinic (CC) experience.
Authors: Lingling Du, Nathan A. Pennell, Paul Elson, Nooshin Hashemi
Journal: Journal of Clinical Oncology (2014)

e12515 Background: The incidence of LC in patients (pts) with LTx is higher than general population. Treatment (trmt) remains controversial given the immunosuppressive state and comorbidities. The goal of this study is to evaluate trmt outcome among LTx pts. Methods: Pts with LC diagnosed at the time of or after LTx were identified using the CC database. LTx-, LC-, and oncologic trmt specifics were collected. Results: Among 847 LTx pts between 2005-2013, 17 (2%) were diagnosed with LC and included in the study: median age at LTx was 61 (range 48-70). LC was found in explanted (ex-)(n=8), native (na-)(n=5), and transplanted (tx-) (n=3) lungs. 1 pt had LC as distant metastasis (mets) only. LC in the na- and tx- lung was detected at a median of 26.7 months (m) (7.9 m -5.4 years) after LTx. Majority were early stage (I/II, n=11), 1 had stage IIIA and 5 were stage IV. NSCLC histology (adeno, squamous, pleomorphic) was more common than SCLC (n=2). Curative trmt was performed as lobectomy in na-LC (n=1) and radiation in tx-LC (n=2). Chemotherapy (CT) was given in 10 pts, primarily carboplatin-based doublets (n=8), along with docetaxel, pemetrexed, or etoposide. Best response in pts who received CT for metastatic disease was progressive disease during trmt in all three (3/3). Upfront adjuvant and palliative CT was given in stage I-II (n=5/11), and stage IV (n= 3/5). In general, pts who received CT had a median survival (MS) of 7.5m ( 95% C.I. 0.3-20.6m) from the start of CT. Anemia was the most common toxicity (30%), and sepsis was most severe (grade 5 in 20%). MS from diagnosis of LC was better in ex-LC than na-/tx- LC: 24m (C.I. 12.9-29m) vs 4.8m (C.I.1.3-13.3m), and more favorable in stage I-IIIA (23.2m) [C.I. 9.4-27.8m] compared to IV ( 2.5m ) [C.I. 1.3-9.7m]. Conclusions: LC detected at the time or after LTx carries various clinical courses. Pts with mets have poor survival and significant toxicities, but variability in outcome still remains. Early stage pts and those with LC in ex-lung should be considered for trmt with modified regimens to decrease the chance of severe adverse events.
Germany sets up new agency to oversee production of medicinal cannabis
Authors: Ned Stafford
Journal: BMJ (2017)

Germany’s Federal Institute for Drugs and Medical Devices, known by the acronym BfArM, is creating an agency to oversee the cultivation of marijuana and the subsequent production of cannabis to be used medicinally, in line with a new law approved by the Bundestag, Germany’s lower house of parliament.

The new law legalises cannabis based medicines to treat pain, nausea from chemotherapy, and other chronic ailments. It mandates that Germany’s massive public health insurance system cover the cost of cannabis medicines prescribed by doctors. Under the previous law cannabis could be used for medical …
Prognostic relevance of molecular characterization of circulating tumor cells (CTC) in head and neck squamous cell carcinoma (HNSCC)
Authors: G. Koutsodontis, A. Strati, G. Papaxoinis, N. Charalambakis, I. Kotsantis, P. Oikonomopoulou, L. Hoxhallari, E. Lianidou, A. Psyrri
Journal: Annals of Oncology (2016)
Comparison of the systemic and local pharmacokinetics, safety and tolerability of clonidine mucoadhesive buccal tablets with reference clonidine oral tablets in healthy volunteers
Authors: B. Petre-Lazar, G. Sharma, S. Hutchings, H. Goodwin, N. Yesiltas Emul, G. Dixon, B. Vasseur
Journal: Annals of Oncology (2016)
Clinical analysis of continuing crizotinib treatment beyond disease progression in ALK-positive non-small-cell lung cancer patients
Authors: L. Hongmei, M. Huang, Y. Xu, X. Zhou, J. Li, J. Wang, F. Peng, Y. Gong, Z. Ding, J. Zhu, P. Yu, L. Li, M. Hou, L. Ren, Y. Wang, Y. Lu
Journal: Annals of Oncology (2016)
A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results.
Authors: Sevil E. Bavbek, Zafar I Malik, Giuseppe Di Lorenzo, Hans-Jorg Scholz, Inge M van Oort, Siobhan Ng, Mustafa Ozguroglu, Winald R. Gerritsen, Stefan Mueller, Timo Marttila, Luis M. Antón Aparicio, Peter Albers, Jürgen E. Gschwend, Samira Bensfia, Evelyne B Ecstein-Fraïssé, Sergio Bracarda, Axel Heidenreich
Journal: Journal of Clinical Oncology (2012)

e15112 Background: In the TROPIC trial (NCT00417079), treatment with CbzP produced a statistically significant improvement in overall survival vs mitoxantrone + prednisone (MP) in patients (pts) with mCRPC previously treated with a docetaxel (D)-containing regimen (HR 0.70; p&lt; 0.0001). These results supported the establishment of 2 programs (based on local regulations): a compassionate use (CUP) and an early access program (EAP; NCT01254279). Methods: The aims of the CUP/EAP are to provide drug to pts with mCRPC who may benefit from CbzP prior to commercial availability and further assess CbzP safety profile. Total enrollment for both programs is estimated at 1600 pts from 250 centers globally. Eligible pts receive CbzP (25 mg/m 2 Q3W + prednisone 10 mg PO QD) until disease progression, death, unacceptable toxicity or physician/pt decision. Results: Baseline characteristics and safety data are available for the first 399 pts: median age was 68 yrs (range 43–89), with 90.2% ECOG PS 0–1. The median cumulative dose of prior D was 675 mg/m 2 ; prior therapy with MP was permitted. For pts whose disease progressed following D, median time from last dose of D to progression was 4 months; 53.3% of pts experienced disease progression either during or &lt; 3 months after D. 61% of pts had ≥ 2 metastatic sites; the most common were bone (93.2%) and regional lymph nodes (34.4%). At the time of analysis, a median of 4 cycles of CbzP had been administered; 4 pts received ≥ 10 cycles. Median relative dose intensity was 99.2% (range 80.1–104.9). G-CSF was administered to 34.3% of pts in Cycle 1 (6.3% therapeutic, 26.6% prophylactic). Overall, 71.4% of pts had adverse events (AEs; all grades). Most common grade 3-4 AEs were neutropenia 11.3%, febrile neutropenia 6.3%, anemia 2.8%, fatigue 2%, neutropenic sepsis 1.8%, vomiting 1.3% and diarrhea 1%. Eight (2%) treatment-related deaths were reported. Conclusions: The CUP/EAP provides additional safety data for CbzP in a routine clinical practice pt population with heavily pre-treated mCRPC. Treatment with CbzP was tolerable, with a predictable and manageable toxicity profile consistent with data reported for TROPIC and the product labeling.
The nationwide cohort of 26,883 patients with sarcomas treated in NETSARC reference network between 2010 and 2015 in France: major impact of multidisciplinary board presentation prior to 1st treatment
Authors: J.-Y. Blay, A. Le Cesne, N. Penel, E. Bompas, C. Chevreau, F. Duffaud, M. Rios, P. Kerbrat, D. Cupissol, P. Anract, J.-E. Kurtz, C. Lebbe, F. Bertucci, S. Piperno-Neumann, P. Rosset, N. Isambert, P. Dubray-Longeras, F. Ducimetière, J.-M. Coindre, A. Italiano
Journal: Annals of Oncology (2016)
Schedule optimization of a novel tumor-targeted IL-2 variant immunocytokine by integration of human in vivo immune cell kinetics and functional imaging
Authors: B. Ribba, C. Boetsch, T. Nayak, Z.-X. Xu, H.-P. Grimm, H. Silber-Baumann, J. Saro, S. Evers, V. Teichgräber
Journal: Annals of Oncology (2016)
The Combination of Siromilus Plus Tacrolimus (SiTac) Improves the Results of Cyclosporine Plus Mycophenolate Mofetil (CsAMMF) After Reduced Intensity Conditioning (RIC) Unrelated Donor Allogeneic Transplantation
Authors: Jose Antonio Perez-Simón, Rodrigo Martino, Rocio Parody, M. Cabrero, Lucía López-Corral, David Valcarcel, Carmen Martinez, Carlos Solano, Rafael De La Camara, Inmaculada Heras, Dolores Caballero, Jordi Sierra
Journal: Blood (2011)
Effect of IL-8 on integrin αvβ3 expression and cell motility via PI3K, Akt, and NF-κB-dependent pathway in human breast cells.
Authors: Nan Shao, Shenming Wang, Yunjian Zhang, Ying Lin
Journal: Journal of Clinical Oncology (2012)

158 Background: αvβ3 integrin-overexpression in tumor associated vasculature is a marker of poor prognosis in breast cancer. A positive correlation between αvβ3 integrin and overexpression of Interleukin-8 (IL-8), a multifunctional cytokine associated with breast cancer aggressiveness was recently demonstrated. Here, we addressed the effects of IL-8 in migration and integrin expression in breast cancer cells. Methods: The IL-8 overexpressing breast cancer cells MDA-MB-231 and HS 578t were treated with IL-8 siRNA and evaluated for cells motility and alterations in the expression of αvβ3. Western Blotting to identify the status of PI3K, Akt and NF-κB. Results: In this study, we found that αvβ3 expression was decreased by IL-8 siRNA, especially the expression of β3. Treatment with αvβ3-blocking antibody LM609 and β3 siRNA significantly reduced invasion in the IL-8 overexpressing cells MDA-MB-231 and HS 578t. The phosphorylation of PI3K, Akt and NF-κB was abrogated after IL-8 siRNA treatment. The IL-8 siRNA can also decrease the binding of β3 promoter and the NF-κB-P65. Conclusions: These results indicate that IL-8 enhances the motility of highly invasive breast cancer cells by regulating αvβ3 expression partially through PI3K/Akt/ NF-κB signal transduction pathway.
miR-28 regulates the germinal center reaction and blocks tumor growth in preclinical models of non-Hodgkin lymphoma
Authors: Nahikari Bartolomé-Izquierdo, Virginia G. de Yébenes, Angel F. Álvarez-Prado, Sonia M. Mur, Juan A. Lopez del Olmo, Sergio Roa, Jesus Vazquez, Almudena R. Ramiro
Journal: Blood (2017)
A Combinational Effect of “Bulk” and “Surface” Shape‐Memory Transitions on the Regulation of Cell Alignment
Authors: Koichiro Uto, Takao Aoyagi, Cole A. DeForest, Allan S. Hoffman, Mitsuhiro Ebara
Journal: Advanced Healthcare Materials (2017)

A novel shape‐memory cell culture platform has been designed that is capable of simultaneously tuning surface topography and dimensionality to manipulate cell alignment. By crosslinking poly(ε‐caprolactone) (PCL) macromonomers of precisely designed nanoarchitectures, a shape‐memory PCL with switching temperature near body temperature is successfully prepared. The temporary strain‐fixed PCLs are prepared by processing through heating, stretching, and cooling about the switching temperature. Temporary nanowrinkles are also formed spontaneously during the strain‐fixing process with magnitudes that are dependent on the applied strain. The surface features completely transform from wrinkled to smooth upon shape‐memory activation over a narrow temperature range. Shape‐memory activation also triggers dimensional deformation in an initial fixed strain‐dependent manner. A dynamic cell‐orienting study demonstrates that surface topographical changes play a dominant role in cell alignment for samples with lower fixed strain, while dimensional changes play a dominant role in cell alignment for samples with higher fixed strain. The proposed shape‐memory cell culture platform will become a powerful tool to investigate the effects of spatiotemporally presented mechanostructural stimuli on cell fate.
Elevated Serum Type I Interferon Activity and Type I Interferon Peripheral Blood Gene Signature In a Subset of Patients with Acquired ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura.
Authors: Contessa E. Edgar, Deirdra Terrell, Sara K. Vesely, Sean Turner, Igor Dozmorov, Timothy B. Niewold, Mark Barton Frank, Melissa Bebak, Wendy Klein, Joan T. Merrill, Kathy L. Moser, Judith A. James, James N. George, A. Darise Farris
Journal: Blood (2010)
A Study of the Proliferative Effect on Acute Lymphocytic Leukemia Cell Lines by G-CSF and Synergetically Anti-Leukemic Effect on These Cell Lines by G-CSF Plus Cytotoxic Agent
Authors: Shengli Xue, Lan Dai, Yan Chen, Qiaocheng Qiu, Suning Chen, XiaoWen Tang, Aining Sun, Wu Depei
Journal: Blood (2010)
NIMG-52. SHARED CARE MODEL FOR GLIOBLASTOMA PATIENT MANAGEMENT
Authors: James Battiste, Erin Dunbar
Journal: Neuro-Oncology (2016)

The incorporation of Tumor Treating Fields (TTFields), an FDA-approved therapy into the treatment algorithm of glioblastoma (GBM) patients, highlights multi-disciplinary treatment complexities and the need for health care delivery models to evolve. GBM patients can be prescribed TTFields by certified prescribing physicians, and be monitored by other providers. Prescribing providers who frequently prescribe TTFields have developed a “Shared Care Model” that can increase access and utilization of TTFields, as well as optimize both the work flow and care of referring and emergency providers. Certified Physicians with substantial TTFields prescribing and clinical experience were selected to formulate consensus information on the shared care model of TTFields for GBM patients. Physician selection criteria included > 2 yrs of experience, > 25 prescriptions, and representing diverse health care delivery systems. In a collaborative process, physicians formulated the Shared Care Model by consensus (> 75% in agreement). Discussions and interviews with current prescribers, and medical staff, identified key areas of patient care: side effect management, imaging guidelines, safety concerns and communication between medical providers. Individual cases highlighted the need for an improved coordination system during care for patients treated with TTFields. Consequently, the authors have begun developing strategies to improve patient care, which include emergency care pocket cards for patients and educational and communication materials for Referring Providers and Emergency Providers. Multidisciplinary treatment is essential to improving outcomes for GBM patients. The utilization of Shared Care Models for treating GBM patients with TTFields, involves patients, prescribing providers, referring providers, and emergency providers with different roles and different locations. Disseminating information to patients and providers on incorporating a Shared Care Model for TTFields has potential to increase access to TTFields, as well as optimize both the work flow and care of referring and emergency providers.
Allogeneic Hemapoietic Progenitor Cell Collection Using Four Different Cell Separators: A Retrospective Comparative Analysis.
Authors: Mutlu Arat, Onder Arslan, Ender A. Soydan, Erol Ayyildiz, Klara Dalva, Meltem Tol, Muhit Ozcan, Günhan Gürman, Taner Demirer, Hamdi Akan, Meral Beksac, Osman Ilhan
Journal: Blood (2004)
The Serine/Threonine Kinase Pim-1 Stabilizes 130 Kilodalton FLT3 and Promotes Aberrant Signaling through STAT5 in Acute Myeloid Leukemia Cells with FLT3 Internal Tandem Duplication: Synergistic Apoptosis Induction by Pim-1 and FLT3 Inhibitors.
Authors: Yingqiu Xie, Mehmet Burcu, Maria R. Baer
Journal: Blood (2009)
Prevalence, pattern, and impact of PD-L1 expression and HPV-status in head and neck squamous cell carcinoma
Authors: T. Chureemas, N. Larbcharoensub, J. Juengsamarn, T. Layangkool, C. Jiarpinitnun, P. Chansriwong, N. Trachu, P. Pattaranutaporn, N. Ngamphaiboon
Journal: Annals of Oncology (2016)
Interleukin-21-Induced Granzyme B-Expressing B Lymphocytes Infiltrate Tumors and Regulate T Cells
Authors: Stefanie Lindner, Karen Dahlke, Kai Sontheimer, Magdalena Hagn, Christof Kaltenmeier, Thomas F.E. Barth, Thamara Beyer, Frank Reister, Dorit Fabricius, Ramin Lotfi, Oleg Lunov, Ulrich Nienhaus, Thomas Simmet, Rolf Kreienberg, Peter Moeller, Hubert Schrezenmeier, Bernd Jahrsdörfer
Journal: Blood (2012)
Children With Tolerance Of Baked Egg Demonstrate Higher Eliciting Doses In Challenges To Native Egg
Authors: Peter S. Capucilli, Jonathan M. Spergel, Terri F. Brown-Whitehorn, Antonella Cianferoni, Joel Fiedler, Laura M. Gober, Nicholas A. Pawlowski, Gita Ram, Rushani W. Saltzman, Jennifer Heimall
Journal: Journal of Allergy and Clinical Immunology (2017)